Compare · BIOL vs MDLN
BIOL vs MDLN
Side-by-side comparison of Biolase Inc. (BIOL) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOL and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN carries a market cap of $49.77B.
- MDLN has hit the wire 25 times in the past 4 weeks while BIOL has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 0 for BIOL).
- Company
- Biolase Inc.
- Medline Inc.
- Price
- -
- $37.84-3.38%
- Market cap
- -
- $49.77B
- 1M return
- -
- +7.21%
- 1Y return
- -
- -7.15%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 25
- Recent ratings
- 0
- 25
Biolase Inc.
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Latest BIOL
- BIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025
- SEC Form 8-K filed by Biolase Inc.
- BIOLASE Voluntarily Initiates Chapter 11 Proceedings
- Biolase Inc. filed SEC Form 8-K: Bankruptcy or Receivership
- SEC Form 8-K filed by Biolase Inc.
- SEC Form 8-K filed by Biolase Inc.
- SEC Form 10-Q filed by Biolase Inc.
- BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen
- Biolase Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biolase Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Latest MDLN
- Large owner Cp Circle Ml Holdco Gp, Llc converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Mozart Coinvestment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- Large owner Tc Group Cayman Investment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Group Inc. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. converted options into 12,128,729 shares and disposed of 12,128,729 units of Class B Common Stock (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- SEC Form 424B4 filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers